The Evolution of Access: AdvaMed Challenges New CMS ‘RAPID’ Framework for Breakthrough Devices
on
By Elise Reuter | Published October 9, 2026
The medical technology industry stands at a critical juncture regarding patient access to life-saving innovation. As the Centers for Medicare & Medicaid Services (CMS) rolls out its latest proposal—the "Regulatory Alignment for Predictable and Immediate Device" (RAPID) pathway—the industry’s primary trade association, AdvaMed, has signaled that while the move is a step in the right direction, it falls short of the systemic reform necessary to bridge the gap between FDA authorization and patient coverage.
For years, the "valley of death" between receiving a breakthrough designation from the Food and Drug Administration (FDA) and securing reimbursement from Medicare has stifled the adoption of cutting-edge technologies. The RAPID proposal is the latest chapter in a long-standing regulatory tug-of-war aimed at ensuring that Medicare beneficiaries—a demographic often the most in need of novel treatments—are not left waiting for the next generation of medical advancements.
The Core Proposal: Understanding the RAPID Pathway
The RAPID program is designed to create a more streamlined, predictable transition for medical devices that have already cleared the rigorous safety and efficacy hurdles of the FDA’s breakthrough designation. With nearly 1,300 devices currently holding this status, the pipeline of potential innovations is vast, covering everything from advanced cardiac implants to neuro-stimulators designed to combat chronic conditions.
Under the current draft, the program establishes specific eligibility criteria that distinguish between device classes. Class II devices—generally those that are moderate-risk—must be enrolled in the FDA’s Total Product Life Cycle Advisory Program (TAP) to qualify for RAPID. Conversely, Class III devices, which are typically high-risk and life-sustaining, are eligible for the pathway regardless of their participation in TAP.
However, the CMS has notably excluded in vitro diagnostics (IVDs) from the program’s scope. This exclusion has become a primary point of contention for industry stakeholders, who argue that diagnostic precision is the bedrock of modern, value-based healthcare. CMS officials currently estimate that 40 devices would immediately qualify for the program, with projections suggesting an additional 20 devices could meet the criteria in the near future.
A Chronology of Coverage: From MCIT to RAPID
To understand the tension surrounding the RAPID proposal, one must examine the turbulent history of device reimbursement policy over the last decade.
The Initial Push: The MCIT Rule
During the first Trump administration, CMS attempted a bold, sweeping reform: the Medicare Coverage of Innovative Technology (MCIT) rule. The proposed policy sought to grant automatic, four-year Medicare coverage to any device that received FDA breakthrough designation. The industry lauded the move as a long-overdue mechanism to ensure immediate patient access.
The Pivot and Retrenchment
The momentum behind MCIT faced a sharp reversal. CMS leadership under the subsequent administration expressed "significant concerns" regarding the clinical evidence supporting these devices, arguing that breakthrough status is a marker of innovation rather than a definitive proof of clinical benefit for the specific Medicare population. The MCIT rule was scrapped, replaced by a more cautious, iterative approach that limited coverage to only five new breakthrough technologies per year. This "Transitional Coverage for Emerging Technology" (TCET) pathway sought to balance innovation with rigorous evidentiary standards, but critics argued it was too slow and restrictive to meet the needs of a rapidly evolving market.
The Current Landscape
The RAPID proposal represents a middle ground. It acknowledges the need for a more efficient pathway than the current TCET framework, yet it maintains guardrails that CMS believes are necessary to protect the fiscal integrity of the Medicare program and ensure that covered devices provide tangible, evidence-based improvements to patient outcomes.
Supporting Data: The Innovation Pipeline
The necessity for a robust coverage pathway is underscored by the sheer volume of innovation currently under review. The FDA’s breakthrough device designation is intended for technologies that provide for more effective treatment or diagnosis of life-threatening or irreversibly debilitating conditions.
Market Scale: With nearly 1,300 devices granted breakthrough status, the current "one-size-fits-all" approach to national coverage determinations (NCDs) is mathematically insufficient.
The Diagnostic Gap: By excluding in vitro diagnostics, the RAPID program leaves out a critical sector of the MedTech industry. Diagnostics often serve as the gatekeepers to therapy; without reimbursement for a diagnostic test, the downstream breakthrough therapy is effectively inaccessible to many patients.
Administrative Lag: Currently, the process for an NCD can take years, creating a "coverage lag" where providers are hesitant to adopt new technologies due to uncertainty regarding reimbursement. RAPID aims to truncate this timeline, though industry leaders argue the current language lacks the necessary binding deadlines.
Official Responses and Industry Pushback
The reaction from the medical device sector has been characterized by "cautious optimism." While the industry welcomes the regulatory attention, the details of the RAPID framework have drawn significant criticism from AdvaMed.
AdvaMed’s Stance
In formal comments submitted to the agency, AdvaMed outlined several critical amendments they believe are essential for the program’s success.
Broadening Eligibility: AdvaMed is calling for a wider net, specifically requesting that diagnostic technologies be included in the RAPID pathway. They argue that excluding diagnostics ignores the shift toward precision medicine.
Mandatory Timelines: A major point of contention is the absence of firm deadlines for the completion of national coverage determinations. AdvaMed argues that without statutory timelines, the process remains vulnerable to administrative delays and bureaucratic inertia.
Funding and Transparency: The association has emphasized that for RAPID to function, it must be adequately funded and operated with high levels of transparency. They are also advocating for "transition protections"—mechanisms to ensure that devices currently navigating existing pathways are not left in a regulatory "no-man’s-land" as the transition to RAPID occurs.
The CEO Perspective
Scott Whitaker, CEO of AdvaMed, encapsulated the industry’s frustration and hope in a recent statement:
"Medicare beneficiaries shouldn’t have to wait for FDA-authorized breakthrough technologies that could improve their health and even save their lives. CMS has taken an important step toward that goal with RAPID, but it must be refined to ensure that the promise of innovation reaches the patient’s bedside without unnecessary delay."
Implications: The Future of Medicare and MedTech
The finalization of the RAPID program will have profound implications for the MedTech ecosystem. If the program is implemented in its current form, it may offer a predictable, albeit narrow, lane for high-risk device entry. However, if the industry’s concerns regarding eligibility and timeline certainty are not addressed, the program may fail to move the needle significantly.
Impact on Investment
The availability of a clear, expedited reimbursement pathway is a primary driver for venture capital in the medical device sector. Investors are often hesitant to back companies that face a multi-year uncertainty regarding Medicare coverage. A robust RAPID program could catalyze investment in early-stage startups that focus on the most challenging-to-treat diseases.
Impact on Patient Outcomes
Ultimately, the debate is centered on patient welfare. The time required for a device to move from an FDA approval letter to a covered Medicare service is a critical variable in public health. Every day that a breakthrough technology is excluded from coverage is a day that a senior citizen may be deprived of a potentially life-saving intervention.
The Regulatory Balancing Act
CMS is walking a tightrope. On one side is the demand for rapid access to innovation; on the other is the agency’s fiduciary responsibility to ensure that the Medicare Trust Fund is not depleted by unproven or over-priced technologies. The RAPID pathway is an attempt to institutionalize this balance. Whether it succeeds will depend on the agency’s willingness to incorporate the feedback from industry stakeholders and ensure that the program remains agile enough to adapt to future scientific breakthroughs.
As the comment period concludes and the industry awaits the final rule, the focus remains on whether the federal government can foster an environment that rewards high-risk, high-reward innovation while maintaining the rigorous standards that have long defined the American healthcare system. The stakes for patients, providers, and manufacturers alike could not be higher.
